+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Dry Eye Syndrome Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2018-2028

  • PDF Icon

    Drug Pipelines

  • 123 Pages
  • December 2022
  • Region: Global
  • GlobalData
  • ID: 5720304
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is a multifactorial disease of the tears and ocular surface that causes ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. The DES market has had few new therapeutics in the last decade. However, the current treatment landscape is anticipated to witness a dramatic progress with the expected launch of numerous pipeline DES drugs during the forecast period, which will be a significant driver of growth in the 7MM.

Anticipated to be a lucrative market given that its prevalence is expected to increase during the forecast period as well as a significant need to introduce new therapy options for the indication. Therefore, the trend of strategic deals in DES is expected to increase during the forecast period as more late-stage pipeline products are anticipated to enter the market during this period.

New pipeline products will help in addressing clinical unmet needs such as need for more therapies. Environmental unmet needs such as need for better diagnostic tools and appropriate clinical trials design are anticipated to be addressed by a combination of the field progressing in terms of disease understanding and product innovations.

Key Highlights

  • The DES market is expected to witness a CAGR of 11.3% from 2018 to 2028, reaching global value of $10.0 billion.
  • The publisher anticipates that 11 pipeline drugs will launch over the forecast period and all of them in the US market. A small proportion of these products are based on known MOAs such as cyclosporine-based formulations, while the other products are based on novel MOAs.
  • While clinical unmet needs such as need for more treatment options are expected to be met by launch of pipeline products in the forecast period, environmental unmet needs such as those for better diagnostic tools are expected to be addressed by a combination of new product launches and improvement in understanding of the disease pathology.
  • There is also an anticipation that as more pipeline therapies move into the critical stages of late-stage development and pre-approvals, some of these companies with particularly promising therapy for DES may enter into some form of strategic partnerships with other companies in order to maximize the potential of commercial success of these products.
Key Questions Answered

  • What are the key unmet needs in DES? Will the products in the current pipeline fill these unmet needs?
  • When will the late stage pipeline products launch, and how will it affect drug sales and the overall DES market in the 7MM?

Scope

  • Overview of DES, including epidemiology, pathophysiology, diagnosis, and disease management.
  • Market Data including annualized DES therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in different patient segments (mild, moderate, severe) forecast from 2018 to 2028.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the DES therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for DES therapy. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global DES therapeutics market: Insightful review of the key industry drivers and barriers. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global DES therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DES therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 DES: Executive Summary - Updated Dec 2022
1.1 Launch of New Pipeline Products and Increasing Prevalence of DES Are Expected to Drive the DES Market Forward
1.2 Pipeline Products with Distinct MOAs Are Likely to Help Companies to Tackle the DES Market
1.3 New Pipeline Products Will Help in Partially Addressing Some Unmet Needs
1.4 Companies Are Undertaking Strategic Deals in Anticipation of Maximizing Sales of DES Products
1.5 What Do Physicians Think?

2 Introduction - Updated Dec 2022
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports

3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Disease Classification

4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 Forecast Methodology
4.4.1 Sources Used
4.4.2 Forecast Assumptions and Methods
4.4.3 Forecast Assumptions and Methods - Total and Diagnosed Prevalent Cases of DES
4.4.4 Forecast Assumptions and Methods - Total and Diagnosed Prevalent Cases of DES by Severity
4.5 Epidemiological Forecast for DES (2018-2028)
4.5.1 Diagnosed Prevalent Cases of DES
4.5.2 Age-Specific Diagnosed Prevalent Cases of DES
4.5.3 Sex-Specific Diagnosed Prevalent Cases of DES
4.5.4 Diagnosed Prevalent Cases of DES by Severity
4.5.5 Total Prevalent Cases of DES
4.5.6 Total Prevalent Cases of DES by Severity
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 Limitations of the Analysis
4.6.3 Strengths of the Analysis

5 Disease Management - Updated Dec 2022, Based on Events up to Dec 1, 2022
5.1 Diagnosis and Treatment Overview
5.1.1 Diagnosis
5.1.2 Treatment Guidelines
5.1.3 Clinical Practice
5.2 US
5.3 5EU
5.4 Japan

6 Competitive Assessment- Updated Dec 2022, Based on Events up to Dec 1, 2022
6.1 Overview
6.1.1 Cyclosporine
6.1.2 LFA-1 Antagonist
6.1.3 Nicotinic Acetylcholine Receptor Agonist Tyrvaya
6.1.4 Mucin Secretagogue
6.1.5 Corticosteroids
6.1.6 Artificial Tears
6.1.7 Autologous Serum

7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 More Treatment Options with Favorable Tolerability Profiles
7.3 Better Diagnostic Tools
7.4 Appropriate Clinical Trial Design
7.5 Simplified Dosing with Cost-Effective Options

8 Pipeline Assessment- Updated Dec 2022, Based on Events up to Dec 1, 2022
8.1 Overview
8.2 Late-Stage Pipeline Products

9 Current and Future Players- Updated Dec 2022, Based on Events up to Dec 1, 2022
9.1 Overview
9.2 Trends in Corporate Strategy
9.3 AbbVie
9.4 Aldeyra Therapeutics
9.5 Alcon
9.6 Bausch Health
9.7 Mitotech
9.8 Novaliq
9.9 Novartis
9.10 Oyster Point Pharma
9.11 RegeneRX Biopharmaceuticals/ReGenTree
9.12 Santen
9.13 Sun Pharmaceutical
9.14 HanAll Biopharma
9.15 Sylentis
9.16 Allysta Pharmaceuticals
9.17 BRIM Biotechnology
9.18 Palatin Technologies

10 Market Outlook- Updated Dec 2022, Based on Events up to Dec 1, 2022
10.1 Global Markets
10.1.1 Forecast
10.1.2 Drivers and Barriers - Global Issues
10.2 US
10.2.1 Forecast
10.2.2 Key Events
10.2.3 Drivers and Barriers
10.3 5EU
10.3.1 Forecast
10.3.2 Key Events
10.3.3 Drivers and Barriers
10.4 Japan
10.4.1 Forecast
10.4.2 Key Events
10.4.3 Drivers and Barriers

11 Appendix

List of Tables
Table 1: DES: Key Metrics in the 7MM
Table 2: Risk Factors and Comorbidities for DES
Table 3: Diagnostic Tests for DES
Table 4: Popular Validated Questionnaires for DES
Table 5: Treatment Guidelines for DES
Table 6: Country Profile - US
Table 7: Country Profile - 5EU
Table 8: Country Profile - Japan
Table 9: Leading Drug Classes Used to Treat DES
Table 10: Comparison of Therapeutic Classes in Development for DES, 2018 - 2028
Table 11: AbbVie’s DES Portfolio Assessment, 2021
Table 12: Aldeyra's DES Portfolio Assessment, 2021
Table 13: Alcon's DES Portfolio Assessment, 2021
Table 14: Bausch Health's DES Portfolio Assessment, 2021
Table 15: Mitotech's DES Portfolio Assessment, 2021
Table 16: Novaliq's DES Portfolio Assessment, 2021
Table 17: Novartis' DES Portfolio Assessment, 2021
Table 18: Oyster Point Pharma's DES Portfolio Assessment, 2021
Table 19: RegeneRX / ReGenTree's DES Portfolio Assessment, 2021
Table 20: Santen's DES Portfolio Assessment, 2021
Table 21: Sun Pharmaceutical's DES Portfolio Assessment, 2021
Table 22: HanAll Biopharma's DES Portfolio Assessment, 2021
Table 23: Sylentis' DES Portfolio Assessment, 2021
Table 24: Allysta Pharmaceuticals' DES Portfolio Assessment, 2021
Table 25: BRIM Biotechnology's DES Portfolio Assessment, 2021
Table 26: Palatin Technologies' DES Portfolio Assessment, 2021
Table 27: DES Market - Global Drivers and Barriers, 2018-2028
Table 28: Key Events Impacting Sales for DES in the US, 2018-2028
Table 29: DES Market - Drivers and Barriers in the US, 2018-2028
Table 30: Key Events Impacting Sales for DES in the 5EU, 2018-2028
Table 31: DES Market - Drivers and Barriers in the 5EU, 2018-2028
Table 32: Key Events Impacting Sales for DES in Japan, 2018-2028
Table 33: DES Market - Global Drivers and Barriers in Japan, 2018-2028
Table 34: The key historical and projected launch dates for DES across the 7MM
Table 35: The key historical and projected patent expiry dates for DES across the 7MM
Table 36: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: Global Sales Forecast by Country for DES in 2018 and 2028
Figure 2: Analysis of the Company Portfolio Gap in DES During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents for DES During the Forecast Period
Figure 4: Vicious Circle of DES
Figure 5: Classification of DES
Figure 6: 9MM, Diagnosed Prevalence of DES, Men and Women, %, Ages =18 Years, 2018
Figure 7: 9MM, Total Prevalence of DES, Men and Women, %, Ages =18 Years, 2018
Figure 8: 9MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of DES
Figure 9: 9MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of DES
Figure 10: 9MM, Sources Used to Forecast the Severity of Diagnosed Prevalent Cases of DES
Figure 11: 9MM, Sources Used to Forecast the Severity of Total Prevalent Cases of DES
Figure 12: 9MM, Diagnosed Prevalent Cases of DES, N, Both Sexes, Ages =18 Years, 2018
Figure 13: 9MM, Diagnosed Prevalent Cases of DES by Age, N, Both Sexes, 2018
Figure 14: 9MM, Diagnosed Prevalent Cases of DES by Sex, N, Ages =18 Years, 2018
Figure 15: 9MM, Diagnosed Prevalent Cases of DES by Severity, N, Ages =18 Years, 2018
Figure 16: 9MM, Total Prevalent Cases of DES, N, Both Sexes, Ages =18 Years, 2018
Figure 17: 9MM, Total Prevalent Cases of DES by Severity, N, Ages =18 Years, 2018
Figure 18: Unmet Needs and Opportunities in DES
Figure 19: Products in Clinical Development for DES, 2022
Figure 20: Key Phase IIb/III Trials for the Promising Pipeline Agents that The Publisher Expects be Licensed for DES in the 7MM During the Forecast Period
Figure 21: Competitive Assessment of the Late-Stage Pipeline Agents that The Publisher Expects to Be Licensed for the Treatment of DES During the Forecast Period
Figure 22: Analysis of the Company Portfolio Gap in DES During the Forecast Period
Figure 23: Number of Deals in DES Market in the 7MM in Prior Years (2011-2022)
Figure 24: Global (7MM) Sales Forecast by Country for DES in 2018 and 2028
Figure 25: Sales Forecast by Drug Class for DES in the US, 2018 and 2028
Figure 26: Sales Forecast by Class for DES in the 5EU in 2018 and 2028
Figure 27: Sales Forecast by Class for DES in Japan in 2018 and 2028

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie
  • Aldeyra Therapeutics
  • Alcon
  • Bausch Health
  • Mitotech
  • Novaliq
  • Novartis
  • Oyster Point Pharma
  • RegeneRX Biopharmaceuticals/ReGen Tree
  • Santen
  • Sun Pharmaceutical
  • HanAll Biopharma
  • Sylentis
  • Allysta Pharmaceuticals
  • BRIM Biotechnology
  • Palatin Technologies